View in EDS PDF Full Text

Editorial: Synthetic peptide vaccine platforms targeting tumor-specific antigens: advances and challenges.

Saved in:
Bibliographic Details
Title: Editorial: Synthetic peptide vaccine platforms targeting tumor-specific antigens: advances and challenges.
Authors: Rubsamen RM; School of Medicine, Case Western Reserve University, Cleveland, OH, United States.; University Hospitals Cleveland Medical Center, Cleveland, OH, United States., Sloan AE; Piedmont Healthcare, Atlanta, GA, United States.
Source: Frontiers in pharmacology [Front Pharmacol] 2024 Feb 23; Vol. 15, pp. 1363282. Date of Electronic Publication: 2024 Feb 23 (Print Publication: 2024).
Publication Type: Editorial
Journal Info: Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38464714
AccessLevel: 2
PubType: Editorial & Opinion
PubTypeId: editorialOpinion
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Editorial: Synthetic peptide vaccine platforms targeting tumor-specific antigens: advances and challenges.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Rubsamen+RM%22">Rubsamen RM</searchLink>; School of Medicine, Case Western Reserve University, Cleveland, OH, United States.; University Hospitals Cleveland Medical Center, Cleveland, OH, United States.<br /><searchLink fieldCode="AU" term="%22Sloan+AE%22">Sloan AE</searchLink>; Piedmont Healthcare, Atlanta, GA, United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101548923%22">Frontiers in pharmacology</searchLink> [Front Pharmacol] 2024 Feb 23; Vol. 15, pp. 1363282. <i>Date of Electronic Publication: </i>2024 Feb 23 (<i>Print Publication: </i>2024).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Editorial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Media]%22">Frontiers Media] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101548923 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>1663-9812 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216639812%22">16639812 </searchLink><i>NLM ISO Abbreviation: </i>Front Pharmacol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38464714
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fphar.2024.1363282
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1363282
    Titles:
      – TitleFull: Editorial: Synthetic peptide vaccine platforms targeting tumor-specific antigens: advances and challenges.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Rubsamen RM
      – PersonEntity:
          Name:
            NameFull: Sloan AE
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 23
              M: 02
              Text: 2024 Feb 23
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 1663-9812
          Numbering:
            – Type: volume
              Value: 15
          Titles:
            – TitleFull: Frontiers in pharmacology
              Type: main
ResultId 1